EA018579B1 - Способ лечения полипов/полипоза и предраковых изменений толстого кишечника - Google Patents
Способ лечения полипов/полипоза и предраковых изменений толстого кишечника Download PDFInfo
- Publication number
- EA018579B1 EA018579B1 EA201001164A EA201001164A EA018579B1 EA 018579 B1 EA018579 B1 EA 018579B1 EA 201001164 A EA201001164 A EA 201001164A EA 201001164 A EA201001164 A EA 201001164A EA 018579 B1 EA018579 B1 EA 018579B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ими
- imichimod
- colon
- cells
- treatment
- Prior art date
Links
- 208000037062 Polyps Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 17
- 208000015768 polyposis Diseases 0.000 title claims description 9
- 241000565118 Cordylophora caspia Species 0.000 title abstract 2
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 210000001072 colon Anatomy 0.000 claims description 18
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- ZXBCLVSLRUWISJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound C1=CC=NC2=C3N(CC(C)C)C(C)=NC3=C(N)N=C21 ZXBCLVSLRUWISJ-UHFFFAOYSA-N 0.000 abstract description 10
- 229950008380 sotirimod Drugs 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract description 3
- 229940124669 imidazoquinoline Drugs 0.000 abstract description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract description 3
- 229940124622 immune-modulator drug Drugs 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 230000000699 topical effect Effects 0.000 abstract description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 229960002751 imiquimod Drugs 0.000 abstract 1
- 229950010550 resiquimod Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 208000014081 polyp of colon Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- -1 IFN-λ (interferon-λ) Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108700025694 p53 Genes Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- KFAJXZVDBVRZRC-UHFFFAOYSA-N 1,5-naphthyridin-4-amine Chemical compound C1=CN=C2C(N)=CC=NC2=C1 KFAJXZVDBVRZRC-UHFFFAOYSA-N 0.000 description 1
- RXNTZIJLOZMJTM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)ethanol Chemical compound C1=CC=C2N(CCO)CC=CC2=C1 RXNTZIJLOZMJTM-UHFFFAOYSA-N 0.000 description 1
- WSIZDLIFQIDDKA-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinolin-2-amine Chemical compound C1=CC=NC2=C(NC(N)=N3)C3=CC=C21 WSIZDLIFQIDDKA-UHFFFAOYSA-N 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000017819 hyperplastic polyp Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US645908P | 2008-01-15 | 2008-01-15 | |
| PCT/EP2008/011088 WO2009089900A1 (en) | 2008-01-15 | 2008-12-23 | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201001164A1 EA201001164A1 (ru) | 2010-12-30 |
| EA018579B1 true EA018579B1 (ru) | 2013-09-30 |
Family
ID=40419193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201001164A EA018579B1 (ru) | 2008-01-15 | 2008-12-23 | Способ лечения полипов/полипоза и предраковых изменений толстого кишечника |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8008319B2 (enExample) |
| EP (1) | EP2237780A1 (enExample) |
| JP (1) | JP2011509956A (enExample) |
| CN (1) | CN101909624A (enExample) |
| AU (1) | AU2008347400B2 (enExample) |
| BR (1) | BRPI0822002A2 (enExample) |
| CA (1) | CA2708559C (enExample) |
| EA (1) | EA018579B1 (enExample) |
| GE (1) | GEP20125605B (enExample) |
| IL (1) | IL205819A (enExample) |
| MX (1) | MX2010007699A (enExample) |
| NZ (1) | NZ586161A (enExample) |
| UA (1) | UA101339C2 (enExample) |
| WO (1) | WO2009089900A1 (enExample) |
| ZA (1) | ZA201003906B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
| CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) * | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU95119625A (ru) * | 1995-11-28 | 1997-07-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Способ лечения полипоза желудочно-кишечного тракта |
| RU2308456C2 (ru) * | 2000-12-08 | 2007-10-20 | 3М Инновейтив Пропертиз Компани | Арилэфирзамещенные имидазохинолины, фармацевтические составы на их основе, способы лечения вирусного заболевания на их основе, способы лечения опухолевого заболевания на их основе |
| RU2006121646A (ru) * | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2078547C1 (ru) * | 1995-11-28 | 1997-05-10 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Способ лечения полипоза желудка и двенадцатиперстной кишки |
| US20040092583A1 (en) * | 2001-01-02 | 2004-05-13 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
-
2008
- 2008-12-23 WO PCT/EP2008/011088 patent/WO2009089900A1/en not_active Ceased
- 2008-12-23 JP JP2010542534A patent/JP2011509956A/ja active Pending
- 2008-12-23 AU AU2008347400A patent/AU2008347400B2/en not_active Ceased
- 2008-12-23 MX MX2010007699A patent/MX2010007699A/es active IP Right Grant
- 2008-12-23 BR BRPI0822002A patent/BRPI0822002A2/pt not_active IP Right Cessation
- 2008-12-23 GE GEAP200811913A patent/GEP20125605B/en unknown
- 2008-12-23 EA EA201001164A patent/EA018579B1/ru not_active IP Right Cessation
- 2008-12-23 CA CA2708559A patent/CA2708559C/en not_active Expired - Fee Related
- 2008-12-23 UA UAA201006372A patent/UA101339C2/ru unknown
- 2008-12-23 NZ NZ586161A patent/NZ586161A/en unknown
- 2008-12-23 CN CN2008801223531A patent/CN101909624A/zh active Pending
- 2008-12-23 EP EP08871156A patent/EP2237780A1/en not_active Withdrawn
-
2009
- 2009-01-14 US US12/353,683 patent/US8008319B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 IL IL205819A patent/IL205819A/en not_active IP Right Cessation
- 2010-06-01 ZA ZA2010/03906A patent/ZA201003906B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU95119625A (ru) * | 1995-11-28 | 1997-07-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Способ лечения полипоза желудочно-кишечного тракта |
| RU2308456C2 (ru) * | 2000-12-08 | 2007-10-20 | 3М Инновейтив Пропертиз Компани | Арилэфирзамещенные имидазохинолины, фармацевтические составы на их основе, способы лечения вирусного заболевания на их основе, способы лечения опухолевого заболевания на их основе |
| RU2006121646A (ru) * | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
Non-Patent Citations (7)
| Title |
|---|
| CARRASCO DANIEL ET AL.: "Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions," JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY ОСТ 2002, vol. 47, no. 4 Suppl, October 2002 (2002-10), pages S212-S216, XP002519594, ISSN: 0190-9622, abstract * |
| DIAKOMANOLIS EMMANUEL ET AL.: "Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream," THE NEW ENGLAND JOURNAL OF MEDICINE 1 AUG 2002, vol. 347, no. 5, 1 August 2002 (2002-08-01), page 374, XP002519595, ISSN: 1533-4406, column 2, paragraph 1 * |
| LIPKA E. ET AL.: "Evaluation of imiquimod and analogues with respect to their oral delivery potential", PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY 1997 US, no. 24, 1997, pages 337-338, XP009I13787, ISSN: 1022-0178, page 337, column 2, paragraph 3 * |
| PFENNINGER JOHN L. ET AL.: "Common anorectal conditions", OBSTETRICS AND GYNECOLOGY, vol. 98, no. 6, December 2001 (2001-12), pages 1130-1139, XP002519596, ISSN: 0029-7844, abstract * |
| PHILLIP R. FLESHNER ET AL.: "Practice Parameters for Anal Squamous Neoplasms", 21 November 2007 (2007-11-21), DISEASES OF THE COLON & RECTUM, SPRINGER-VERLAG, NE, PAGE(S) 2-9, XP019568130, ISSN: 1530-0358, page 5, paragraph 2, page 6, paragraph 4 * |
| SIDKY Y. A. ET AL.: "INHIBITION OF MURINE TUMOR GROWTH BY AN INTERFERON-INDUCING IMIDAZOQUINOLINAMINE", CANCER RESEARCH, vol. 52, no. 13, 1992, pages 3528-3533, XP002519208, ISSN: 0008-5472, abstract * |
| ЛЮБЧЕНКО Л.Н. Клинико-генотипические варианты семейного рака толстой кишки, Практическая онкология, т. 6, No. 2, 2005, с. 132-136 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0822002A2 (pt) | 2015-10-13 |
| WO2009089900A1 (en) | 2009-07-23 |
| MX2010007699A (es) | 2010-08-04 |
| NZ586161A (en) | 2012-05-25 |
| CA2708559C (en) | 2015-10-06 |
| GEP20125605B (en) | 2012-08-10 |
| JP2011509956A (ja) | 2011-03-31 |
| EP2237780A1 (en) | 2010-10-13 |
| IL205819A0 (en) | 2010-11-30 |
| EA201001164A1 (ru) | 2010-12-30 |
| ZA201003906B (en) | 2011-03-30 |
| AU2008347400A1 (en) | 2009-07-23 |
| US8008319B2 (en) | 2011-08-30 |
| CA2708559A1 (en) | 2009-07-23 |
| IL205819A (en) | 2013-02-28 |
| AU2008347400B2 (en) | 2014-12-11 |
| US20090182005A1 (en) | 2009-07-16 |
| UA101339C2 (ru) | 2013-03-25 |
| CN101909624A (zh) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA018579B1 (ru) | Способ лечения полипов/полипоза и предраковых изменений толстого кишечника | |
| Williams et al. | Estrogen receptor beta as target for colorectal cancer prevention | |
| Fan et al. | Low‐dose decitabine‐based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report | |
| Cheng et al. | Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-κB signaling pathway | |
| Choi et al. | Synergistic activity of paclitaxel, sorafenib, and radiation therapy in advanced renal cell carcinoma and breast cancer | |
| Şenol et al. | The role of inflammation in gastric cancer | |
| Ahmed et al. | Ginkgo biloba L. leaf extract offers multiple mechanisms in bridling N-methylnitrosourea–mediated experimental colorectal cancer | |
| Ghazizadeh et al. | Xanthomicrol exerts antiangiogenic and antitumor effects in a mouse melanoma (B16F10) allograft model | |
| Qi et al. | Huaier granule combined with tegafur gimeracil oteracil potassium promotes stage IIb gastric cancer prognosis and induces gastric cancer cell apoptosis by regulating livin | |
| Schrump et al. | Targeting the epigenome for the treatment and prevention of lung cancer | |
| Lin et al. | Shrimp anti-lipopolysaccharide factor peptide enhances the antitumor activity of cisplatin in vitro and inhibits HeLa cells growth in nude mice | |
| Liu et al. | Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells | |
| Shelton | Introduction to colorectal cancer | |
| JP7285001B2 (ja) | サフラナール製剤による肝臓癌治療の方法 | |
| Sun et al. | The role of NLRP3 inflammasome in digestive system malignancy | |
| Abou-Issa et al. | Celecoxib: a novel treatment for lung cancer | |
| Prabhu et al. | Targeting NF-κB mediated cell signaling pathway and inflammatory mediators by 1, 2-diazole in A549 cells in vitro | |
| HK1151220A (en) | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives | |
| CN115282280A (zh) | TGF-β1信号抑制剂的新用途 | |
| KR20190071852A (ko) | 고미신 g 화합물을 유효성분으로 포함하는 유방암, 췌장암, 대장암 및 전립선암 치료용 조성물 | |
| Feng et al. | Liriope muscari baily saponin C induces apoptosis and autophagy in HCT116 cells via ROS generation | |
| Cerda-Cruz et al. | Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug | |
| Mbodi et al. | An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance | |
| Patwardhan et al. | Anticancer activities of macromolecules of marine origin: Clinical evidence | |
| Sara et al. | The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: An experimental study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |